We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+5.65%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$4.8B
AUM Growth
-$96.5M
Cap. Flow
+$4.8M
Cap. Flow %
0.1%
Top 10 Hldgs %
55.46%
Holding
84
New
7
Increased
20
Reduced
15
Closed
24

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$87.1M
2
BRKR icon
Bruker
BRKR
+$85.7M
3
PTCT icon
PTC Therapeutics
PTCT
+$67.6M
4
AXSM icon
Axsome Therapeutics
AXSM
+$52.6M
5
OBIO icon
Orchestra BioMed
OBIO
+$47.7M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$81.8M
2
GMED icon
Globus Medical
GMED
+$55.5M
3
RGNX icon
Regenxbio
RGNX
+$41.9M
4
ILMN icon
Illumina
ILMN
+$39.6M
5
BCYC
Bicycle Therapeutics
BCYC
+$37.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$351M 7.31%
3,272,104
-82,199
-2% -$9.46M
PTCT icon
2
PTC Therapeutics
PTCT
$6.33B
$344M 7.16%
7,093,298
+1,477,911
+26% +$67.6M
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$37.7B
$337M 7.02%
1,683,362
– –
RCKT icon
4
Rocket Pharmaceuticals
RCKT
$360M
$303M 6.31%
17,687,772
– –
IMCR icon
5
Immunocore
IMCR
$1.76B
$279M 5.82%
5,649,943
+90,621
+2% +$5.1M
MASI
6
DELISTED
Masimo
MASI
$277M 5.77%
1,501,493
– –
AXSM icon
7
Axsome Therapeutics
AXSM
$12.3B
$233M 4.86%
3,780,855
+800,373
+27% +$52.6M
PEN icon
8
Penumbra
PEN
$12.6B
$188M 3.91%
673,371
-25,000
-4% -$6.38M
ARGX icon
9
argenx
ARGX
$56.4B
$180M 3.74%
482,195
– –
RARE icon
10
Ultragenyx Pharmaceutical
RARE
$2.67B
$171M 3.57%
4,270,996
+304,081
+8% +$13M
TMO icon
11
Thermo Fisher Scientific
TMO
$209B
$167M 3.48%
290,334
-145,166
-33% -$81.8M
ESTA icon
12
Establishment Labs
ESTA
$2.7B
$162M 3.37%
2,389,138
+15,000
+0.6% +$1.03M
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$4.39B
$155M 3.23%
8,242,864
+4,571,926
+125% +$87.1M
NTRA icon
14
Natera
NTRA
$37.1B
$145M 3.02%
2,611,783
+2,500
+0.1% +$120K
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$135M 2.82%
3,643,114
– –
CLDX icon
16
Celldex Therapeutics
CLDX
$2.82B
$111M 2.31%
3,084,215
– –
PTGX icon
17
Protagonist Therapeutics
PTGX
$8.79B
$106M 2.2%
4,600,799
+1,008,813
+28% +$16.9M
OBIO icon
18
Orchestra BioMed
OBIO
$229M
$100M 2.09%
5,118,507
+4,118,507
+412% +$47.7M
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$98M 2.04%
6,387,178
+781,612
+14% +$17.2M
VCEL icon
20
Vericel Corp
VCEL
$2.33B
$96.5M 2.01%
3,291,873
+191,969
+6% +$5.56M
BRKR icon
21
Bruker
BRKR
$9.17B
$93.6M 1.95%
+1,187,342
New +$85.7M
CYTK icon
22
Cytokinetics
CYTK
$11.1B
$90.6M 1.89%
2,574,198
– –
ILMN icon
23
Illumina
ILMN
$28.8B
$87.5M 1.82%
386,785
-193,393
-33% -$39.6M
AVDL
24
DELISTED
Avadel Pharmaceuticals
AVDL
$52.6M 1.1%
5,741,939
– –
TXG icon
25
10x Genomics
TXG
$5.84B
$51.8M 1.08%
929,286
+56,694
+6% +$2.65M
1
2 3 4

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q1 2023 Portfolio in Review

As of Q1 2023, RTW Investments held 84 positions worth $4.8B, down 2% from $4.9B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RTW Investments's Q1 2023 filing shows 7 new, 20 increased, 15 reduced and 24 closed positions. Its largest new stake was Bruker: 1,187,342 shares worth $93.6M. The largest sale was Thermo Fisher Scientific, an estimated $81.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q1 2023 buy was Bruker: 1,187,342 shares worth $93.6M.
  • RTW Investments added most to Acadia Pharmaceuticals in Q1 2023, an estimated $87.1M increase.
  • RTW Investments's biggest Q1 2023 reduction was Thermo Fisher Scientific, cutting an estimated $81.8M.
  • RTW Investments fully exited Globus Medical in Q1 2023, selling an estimated $55.5M.
  • RTW Investments's ten largest holdings make up 55% of its $4.8B portfolio in Q1 2023.
  • RTW Investments opened 7 new positions and closed 24 in Q1 2023.
  • RTW Investments's portfolio value fell 2% quarter-over-quarter to $4.8B.

Based on RTW Investments's 13F filing for Q1 2023, filed 15 May 2023.